Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum membrane Single-pass type II membrane protein |
Domain |
PF11838 ERAP1-like C-terminal domain PF01433 Peptidase family M1 |
Function |
Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. Preferentially hydrolyzes the basic residues Arg and Lys. |
Biological Process |
GO:0002250 adaptive immune response GO:0002474 antigen processing and presentation of peptide antigen via MHC class I GO:0002483 antigen processing and presentation of endogenous peptide antigen GO:0003013 circulatory system process GO:0008015 blood circulation GO:0008217 regulation of blood pressure GO:0019882 antigen processing and presentation GO:0019883 antigen processing and presentation of endogenous antigen GO:0019885 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0043171 peptide catabolic process GO:0048002 antigen processing and presentation of peptide antigen GO:1901565 organonitrogen compound catabolic process |
Molecular Function |
GO:0004175 endopeptidase activity GO:0004177 aminopeptidase activity GO:0008235 metalloexopeptidase activity GO:0008237 metallopeptidase activity GO:0008238 exopeptidase activity GO:0033218 amide binding GO:0042277 peptide binding GO:0070006 metalloaminopeptidase activity |
Cellular Component |
GO:0005788 endoplasmic reticulum lumen |
KEGG | - |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-983170: Antigen Presentation R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-168256: Immune System |
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ERAP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between ERAP2 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ERAP2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ERAP2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of ERAP2 in various data sets.
|
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ERAP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ERAP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ERAP2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ERAP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ERAP2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ERAP2 |
Name | endoplasmic reticulum aminopeptidase 2 |
Aliases | L-RAP; LRAP; leukocyte-derived arginine aminopeptidase |
Chromosomal Location | 5q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ERAP2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |